TET3 and acute myeloid leukemia: Since some of the samples showed a lower 5-hmC levels despite a high TET2 mRNA expression even in the absence of TET2 mutations, we also studied the expression of other paralogs of TET2— expression of TET1 did not vary significantly across the patient groups studies, and analysis of publicly available AML-MR and MDS datasets did not show any significant alteration of TET3 expression in AML-MR and MDS when compared to healthy controls.